BR112016027772A2 - Composto; método para reduzir a biomassa de um biofilme; método para a promoção da dispersão de microorganismos a partir de um biofilme; método para aniquilar um microorganismo dentro de um biofilme; método de sensibilização de um microrganismo em um biofilme a um agente antimicrobiano; método para inibir a formação de um biofilme; método de remoção ou eliminação de um biofilme existente e inibição da formação de biofilme; método para matar células persister microbianas, ou inibir o crescimento de células persister microbianas; utilização de um composto de um composto; dispositivo médico; composição farmacêutica; método de preparação de um composto - Google Patents

Composto; método para reduzir a biomassa de um biofilme; método para a promoção da dispersão de microorganismos a partir de um biofilme; método para aniquilar um microorganismo dentro de um biofilme; método de sensibilização de um microrganismo em um biofilme a um agente antimicrobiano; método para inibir a formação de um biofilme; método de remoção ou eliminação de um biofilme existente e inibição da formação de biofilme; método para matar células persister microbianas, ou inibir o crescimento de células persister microbianas; utilização de um composto de um composto; dispositivo médico; composição farmacêutica; método de preparação de um composto

Info

Publication number
BR112016027772A2
BR112016027772A2 BR112016027772A BR112016027772A BR112016027772A2 BR 112016027772 A2 BR112016027772 A2 BR 112016027772A2 BR 112016027772 A BR112016027772 A BR 112016027772A BR 112016027772 A BR112016027772 A BR 112016027772A BR 112016027772 A2 BR112016027772 A2 BR 112016027772A2
Authority
BR
Brazil
Prior art keywords
biofilm
compound
formation
microorganism
persister cells
Prior art date
Application number
BR112016027772A
Other languages
English (en)
Portuguese (pt)
Inventor
Holmes Ian
Naylor Alan
Negoita-Giras Gabriel
Powell Jonathan
Charles Ian
Alber Dagmar
Original Assignee
Auspherix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1409402.3A external-priority patent/GB201409402D0/en
Priority claimed from GB201501967A external-priority patent/GB201501967D0/en
Application filed by Auspherix Ltd filed Critical Auspherix Ltd
Publication of BR112016027772A2 publication Critical patent/BR112016027772A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/12—Gold compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112016027772A 2014-05-28 2015-05-28 Composto; método para reduzir a biomassa de um biofilme; método para a promoção da dispersão de microorganismos a partir de um biofilme; método para aniquilar um microorganismo dentro de um biofilme; método de sensibilização de um microrganismo em um biofilme a um agente antimicrobiano; método para inibir a formação de um biofilme; método de remoção ou eliminação de um biofilme existente e inibição da formação de biofilme; método para matar células persister microbianas, ou inibir o crescimento de células persister microbianas; utilização de um composto de um composto; dispositivo médico; composição farmacêutica; método de preparação de um composto BR112016027772A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1409402.3A GB201409402D0 (en) 2014-05-28 2014-05-28 Anti-bacterial compounds
GB201501967A GB201501967D0 (en) 2015-02-06 2015-02-06 Anti-bacterial compounds
PCT/GB2015/051551 WO2015181551A1 (en) 2014-05-28 2015-05-28 Gold (i)-phosphine compounds as anti-bacterial agents

Publications (1)

Publication Number Publication Date
BR112016027772A2 true BR112016027772A2 (pt) 2017-08-15

Family

ID=53284306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027772A BR112016027772A2 (pt) 2014-05-28 2015-05-28 Composto; método para reduzir a biomassa de um biofilme; método para a promoção da dispersão de microorganismos a partir de um biofilme; método para aniquilar um microorganismo dentro de um biofilme; método de sensibilização de um microrganismo em um biofilme a um agente antimicrobiano; método para inibir a formação de um biofilme; método de remoção ou eliminação de um biofilme existente e inibição da formação de biofilme; método para matar células persister microbianas, ou inibir o crescimento de células persister microbianas; utilização de um composto de um composto; dispositivo médico; composição farmacêutica; método de preparação de um composto

Country Status (13)

Country Link
US (1) US20170226133A1 (enExample)
EP (1) EP3148555A1 (enExample)
JP (1) JP2017529357A (enExample)
KR (1) KR20170008762A (enExample)
CN (1) CN106573944A (enExample)
AU (1) AU2015265715A1 (enExample)
BR (1) BR112016027772A2 (enExample)
CA (1) CA2950385A1 (enExample)
EA (1) EA201692189A1 (enExample)
IL (1) IL249199A0 (enExample)
MX (1) MX2016015626A (enExample)
SG (1) SG11201609387UA (enExample)
WO (1) WO2015181551A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143889A1 (en) 2007-05-14 2008-11-27 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
EP3253214A1 (en) * 2015-02-06 2017-12-13 Auspherix Limited Methods for the inhibition and dispersal of biofilms using auranofin
EP3346840A4 (en) * 2015-09-08 2019-03-13 Nanyang Technological University PROCESS FOR INHIBITING THE QUORUM DETECTION IN PSEUDOMONAS AERUGINOSA
GB201521238D0 (en) * 2015-12-02 2016-01-13 Auspherix Ltd Anti-bacterial compounds
US20200368249A1 (en) * 2017-06-26 2020-11-26 Kyle H. ROHDE Activity of gold-complexed compounds against mycobacterium tuberculosis and mycobacterium abscessus
CN109970771B (zh) * 2019-04-12 2021-07-13 云南大学 多醚链取代的炔基金（i）配合物及其制备方法与应用
DE102019120052A1 (de) 2019-07-24 2021-01-28 SchäferRolls GmbH & Co. KG Technische Walze, insbesondere für die Papierherstellung, Verfahren zum Einbringen einer Polymerfaser in ein Leerrohr einer technischen Walze und Verwendung einer Polymerfaser
CN110974838B (zh) * 2019-12-02 2021-04-13 南方科技大学 金化合物在制备抗菌剂中的应用
CN113135958B (zh) * 2021-04-08 2022-05-27 南京中医药大学 氮杂环卡宾硒-金化合物在制备抗耐碳青霉烯类鲍曼不动杆菌药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883546A (en) * 1973-08-01 1975-05-13 Smithkline Corp S-heterocyclic derivatives of phosphine or phosphite gold mercaptides
WO1995014703A1 (en) * 1993-11-24 1995-06-01 Luminis Pty. Ltd. Triorganophosphinegold (i) thionucleobases with anti-tumor activity

Also Published As

Publication number Publication date
MX2016015626A (es) 2017-07-04
EA201692189A1 (ru) 2017-02-28
KR20170008762A (ko) 2017-01-24
EP3148555A1 (en) 2017-04-05
WO2015181551A1 (en) 2015-12-03
SG11201609387UA (en) 2016-12-29
CA2950385A1 (en) 2015-12-03
US20170226133A1 (en) 2017-08-10
IL249199A0 (en) 2017-01-31
JP2017529357A (ja) 2017-10-05
AU2015265715A1 (en) 2016-11-24
CN106573944A (zh) 2017-04-19

Similar Documents

Publication Publication Date Title
BR112016027772A2 (pt) Composto; método para reduzir a biomassa de um biofilme; método para a promoção da dispersão de microorganismos a partir de um biofilme; método para aniquilar um microorganismo dentro de um biofilme; método de sensibilização de um microrganismo em um biofilme a um agente antimicrobiano; método para inibir a formação de um biofilme; método de remoção ou eliminação de um biofilme existente e inibição da formação de biofilme; método para matar células persister microbianas, ou inibir o crescimento de células persister microbianas; utilização de um composto de um composto; dispositivo médico; composição farmacêutica; método de preparação de um composto
BR112018075297A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção bacteriana
MA41988A (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
BR112013010977A2 (pt) "compostos antimicrobiais com armazenamento estável incluindo compostos de ceragenin e métodos de uso".
NI201200146A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
MA39777A (fr) Composes organiques de la famille des monobactams pour le traitement d'infections bactériennes
BR112017003931A2 (pt) composições de surfactante aquoso
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
BR112015007742B1 (pt) composto, composição farmacêutica, e, uso do referido composto
MX375153B (es) Compuestos antihelminticos.
MX377581B (es) Compuestos antihelmínticos y composiciones y método de uso de los mismos.
MX2015017512A (es) Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk.
MA37213B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX383928B (es) Derivado de piridona que tiene un grupo tetrahidropiranilmetilo.
BR112015028214A2 (pt) inibidores de acc e usos dos mesmos
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
BR112013001341A2 (pt) compostos de pirimidina como inibidores de proteínas quinases ikk épsilon e/ou tbk-1, processo para a preparação dos mesmos e suas composições farmacêuticas
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
MX2016015625A (es) Compuestos de oro (i)-fosfina como agentes antibacterianos.
BR112017005441A2 (pt) método para transformar uma célula de planta ou tecido de planta usando agrobacterium, planta transgênica, célula transgênica ou tecido transgênico, meio de cultura, e, uso de um método.
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
MX372755B (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap).
BRPI1006626B8 (pt) uso de um antibiotico fluoroquinolona para a produção de um medicamento para tratar uma infecção bacteriana pulmonar
PL407699A1 (pl) Sposób otrzymywania 7-O-ß-D-glukopiranozylo-5-hydroksy-4'-metoksyizoflawonu i 5-O-ß-D-glukopiranozylo-7-hydroksy-4'-metoksyizoflawonu

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]